Intellectual property rights as a driver of innovation in the 21st century
Small and medium-sized enterprises (SMEs) are the foundation of the European economy, and in Switzerland, they account for 95% of the country’s economic output. SMEs and companies can increase their profits by integrating, incorporating, or licensing intellectual property (IP) rights. The benefits of intellectual property have long been known, they promote competition, increase profits, protect companies’ R&D investments, strengthen the economy, and help address global challenges.
In 2022, Switzerland once again topped the Global Innovation Index. CSEM is a key player in this innovative ecosystem thanks to its ability to translate technical solutions into business results. This year, we filed 17 new patent families in fields as diverse as electronics and Internet of Things devices, machine vision, life science tools, additive manufacturing, mechanical watches, photovoltaics, and digital energy. We also worked hard to improve our patent processes to increase their impact.
CSEM’s strength lies in its ability to deliver customized, commercially focused solutions. The solid results achieved by our IP portfolio over the past five years are the direct result of our unique collaboration with Swiss industry and academia. By continuously adapting our IP portfolio, licensed technologies, and sharing our knowledge, we are helping Swiss SMEs make an impact on society.
One example is Dr. Franz Xaver Pengg’s patented invention, which was recognized by the 2022 CSEM Inventor Award. His invention is a key component of CSEM’s icyTRX ultra-low-power transceiver. IcyTRX can be integrated into Bluetooth™ chips, enabling their miniaturization. The technology can also help extend the battery life of wearable devices such as hearing aids. Since its development, icyTRX has been sold under license and is one of CSEM’s most notable commercial successes.
Another technology in CSEM’s IP portfolio is optical blood pressure monitoring technology, which has already been licensed to two successful private companies. CSEM’s technology enables cuff-free blood pressure monitoring to address endemic hypertension and improve patient outcomes.